Membrane association of a model CD4(+) T cell vaccine antigen confers enhanced yet incomplete protection against Murid Herpesvirus-4 infection
- Author(s)
- Yunis, J; Redwood, AJ; Belz, GT; Stevenson, PG;
- Details
- Publication Year 2020-01-29,Volume 98,Issue #4,Page 332-343
- Journal Title
- Immunology and Cell Biology
- Publication Type
- Journal Article
- Abstract
- Vaccination against Y-herpesviruses has proved difficult. CD4(+) T cells are essential to contain infection, but how best to prime them and whether this can reduce viral loads remain unclear. To address these questions, we used ovalbumin (OVA) as a model antigen, delivering it with Murine cytomegalovirus (MCMV) to protect mice against OVA-expressing Murine Herpesvirus-4 (MuHV-4). Membrane-associated OVA (mOVA) was more effective than soluble OVA, both to prime CD4(+) T cells and as an effector target. It was also a better target than an OVA epitope limited to infected cells, suggesting that protective CD4(+) T cells recognize infected cell debris rather than infected cells themselves. While MCMV-mOVA protected acutely against MuHV-4-mOVA, long-term protection was incomplete, even when OVA-specific CD8(+) T cells and B cells were also primed. Thus, even optimized single target vaccines may poorly reduce long-term Y-herpesvirus infections.
- Keywords
- CD4+ T cell; gamma-herpesvirus; vaccine
- Research Division(s)
- Immunology
- PubMed ID
- 31997396
- Publisher's Version
- https://doi.org/10.1111/imcb.12319
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2020-05-04 11:46:59
Last Modified: 2020-05-04 02:34:06